Comparative Pharmacology
Head-to-head clinical analysis: SEMPREX D versus TAVIST ALLERGY SINUS HEADACHE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEMPREX D versus TAVIST ALLERGY SINUS HEADACHE.
SEMPREX-D vs TAVIST ALLERGY/SINUS/HEADACHE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEMPREX-D combines acrivastine, a histamine H1 receptor antagonist, and pseudoephedrine, a sympathomimetic amine vasoconstrictor. Acrivastine blocks peripheral histamine-mediated effects, while pseudoephedrine constricts nasal blood vessels to reduce congestion.
TAVIST ALLERGY/SINUS/HEADACHE contains clemastine fumarate (first-generation antihistamine) that competitively antagonizes histamine at H1 receptors, and acetaminophen that inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and fever; phenylpropanolamine is an alpha-adrenergic agonist that causes vasoconstriction of nasal mucosa.
1 capsule orally every 12 hours; each capsule contains acrivastine 8 mg and pseudoephedrine 60 mg.
1 tablet (acetaminophen 500 mg, diphenhydramine 12.5 mg, phenylephrine 10 mg) orally every 4-6 hours as needed; maximum 4 tablets per day
None Documented
None Documented
Terminal elimination half-life is approximately 8-12 hours, allowing twice-daily dosing.
5-7 hours for clemastine; 12-15 hours for pseudoephedrine; acetaminophen half-life 2-3 hours. Context: Clemastine half-life supports twice-daily dosing; pseudoephedrine's longer half-life allows 6-8 hour dosing intervals
Renal (approx. 60% as unchanged drug and metabolites), biliary/fecal (approx. 40%).
Renal excretion of unchanged drug and metabolites accounts for 70-80%, with 15-25% fecal elimination; bilary excretion contributes to remaining
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine/Decongestant Combination